Research
BTIG Downgrades Theravance Biopharma to Neutral From Buy
BTIG Downgrades Theravance Biopharma to Neutral From Buy
$TBPH
$TBPH
2 stories mentioning TBPHUpdated just now
Every FINWIRES story that references TBPH, newest first.
Sectors
Sector Update: Healthcare Stocks Edge Higher Premarket Monday
Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) advancing by 0.3%.BridgeBio Pharma (BBIO) stock was up 3.8% after the company said it has met the primary endpoint in a late-stage trial of the oral drug infigratinib, for the treatment of children living with achondroplasia, or bone dwarfism.Viridian Therapeutics (VRDN) shares were up more than 8% after the company said Lumvoa received approval from the US Food and Drug Administration to treat thyroid eye disease, an autoimmune disease.Zymeworks (ZYME) has signed a definitive agreement to acquire Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 5% and Theravance Biopharma stock fell 3.5% pre-bell.
$BBIO$IBB$TBPH$VRDN$XLV$ZYME
